An interventional study of Urolithin A and Placebo in Muscle Loss in Elderly, Geriatric Health and Elderly (People Aged 65 or More), sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Not yet recruiting. Open to participants aged 65 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will determine whether oral urolithin A (UA) attenuates the loss of knee-extensor strength caused by 10 days of horizontal bed rest in older adults.
The randomized comparison will also assess muscle mass, cardiorespiratory fitness, physical performance and glucose tolerance, together with cellular mechanisms of muscle adaptation. Orthostatic tolerance, balance responses to galvanic vestibular stimulation (GVS), salivary cortisol, and oral and fecal microbiome profiles will provide complementary exploratory measures of adaptation and recovery.v
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in BR-UA group will receive a total of 1,000 mg of UA orally each day.
Dietary Supplement: Urolithin A
Participants in group "C" will receive matching placebo.
Dietary Supplement: Placebo
1000mg Urolithin A daily
Also known as: Mitopure
Placebo
Changes in knee extensor strength using biodex at baseline and following the intervention.
To determine whether UA supplementation reduces the percentage loss of maximal voluntary isometric knee-extensor strength (N) using Biodex between baseline and recovery, compared with placebo.
Time frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
Changes in V02 using indirect calorimetry at baseline and following the intervention.
To compare the effects of UA and placebo on cardiorespiratory fitness function using peak oxygen uptake (VO2peak) between baseline and recovery, compared with placebo.
Time frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
Changes in body composition using DEXA scan at baseline and following the intervention.
To determine whether UA supplementation had an effect on changes in fat free mass and fat mass using the DEXA scan between baseline and recovery, compared with placebo.
Time frame: Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
Changes in mitochondrial respiration at baseline and following the intervention.
To determine whether UA supplementation had an effect on changes in mitochondrial respiration and function using the OROBORUS from muscle biopsy samples between baseline and recovery, compared with placebo.
Time frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
Changes in muscle mass at baseline and following the intervention.
To determine whether UA supplementation had an effect on changes in muscle mass using CT scan between baseline and recovery, compared with placebo.
Time frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)
No study locations are listed for this record.
Plan to share: No
Start is estimated for Aug 2027; primary completion for Aug 2031, 48 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Urolithin A Supplement
McGill University Health Centre/Research Institute of the McGill University Health Centre →